Posmeal MD

Uses
Posmeal MD (Voglibose) is an alpha-glycosidase inhibitor and is used to reduce the blood glucose level after a meal in patients with diabetes. Posmeal MD (Voglibose) contains glucose absorption, thereby decreasing the risks of macrovascular complications. Hyperglycemia is mostly related to the first phase of insulin release. Alpha-glycosidase inhibitors suppress glucose absorption in the intestines, preventing sharp increases in glucose levels after a meal. This group of medications includes Acarbose, Miglitol, and Voglibose. Voglibose is the most recent medication in the group. It has more side effects when compared to Acarbose and Miglitol, however it is more effective. There have been a few studies, supporting the idea of using Voglibose for hyperglycemia after meals. Moreover, it has been discovered that it is hyperglycemia after meals and not fasting blood glucose level is the marker of diabetes-related cardiovascular disorders.

Dosage and Administration
Posmeal MD (Voglibose) is manufactured in the form of tablets that are taken by mouth before every meal with a full glass of water.

The standard initial dose prescribed to adults amounts to 0.2mg three times per day. However, occasionally this dose may not be sufficient to achieve the desired treatment effect. In this case, your physician may increase your dose up to 0.3mg three times per day, but such an increase will require careful monitoring of the patient's condition.

The standard initial dose prescribed to elderly patients amounts to 0.1mg three times per day. However, occasionally this dose may not be sufficient to achieve the desired treatment effect. In this case, your physician may increase your dose up to 0.2-0.3mg three times per day, but such an increase will require careful monitoring of the patient's condition.

Side effects
Side effects are the symptoms and the problems that may occur while taking medications. Most medications used to treat any diseases may cause certain side effects. The most common side effects caused by Posmeal MD (Voglibose) include:

• Metabolic disorders, such as hypoglycaemia.
• Gastro-intestinal tract disorders, such as bloating, flatulence, diarrhea, and bowel obstruction.
• Hepatobiliary system disorders, such as fulminant hepatitis, severely impaired liver function, elevated liver transaminase levels (aspartate aminotransferase, alanine aminotransferase), and jaundice.

Posmeal MD (Voglibose) should not be used without proper and regular medical supervision. If you notice any side effects please contact your physician immediately.

Precautions
Posmeal MD (Voglibose) can be prescribed during pregnancy and to patients who suspect they are pregnant, however this is justified only when the expected treatment results exceed any potential threats. There is no available data on whether this medication is safe to be used in pregnant patients.

It is also recommended to avoid prescribing Posmeal MD (Voglibose) to women during breastfeeding. However, if there is no way to avoid it breastfeeding has to be stopped.

Some of the side effects triggered by Posmeal MD (Voglibose) may affect the patient's ability to drive motor vehicles and operate machinery.

There is not available data on the use of Posmeal MD (Voglibose) in children, therefore the medication should not be prescribed to pediatric patients.

In case of overdose, please contact your physician immediately.